Dataset from Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

The primary objectives of this study are to evaluate the efficacy of filgotinib in the
induction and maintenance treatment of moderately to severely active ulcerative colitis (UC)
in participants who are biologic-naive and biologic-experienced.

Participants who complete the study, or met protocol specified efficacy discontinuation
criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead
Study GS-US-418-3899: NCT02914535).